Experimental antidote for blood thinners tested in early trial
NCT ID NCT04593784
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a drug called ciraparantag to see if it could quickly reverse the effects of blood thinners in 41 healthy adults. Participants received either ciraparantag or a placebo, and their blood clotting time was measured. The study was terminated early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ciraparantag (a drug given intravenously to reverse the effects of blood thinners)
What this could lead to
If successful, ciraparantag could become a quick-acting antidote for certain blood thinners, potentially helping in emergencies where rapid reversal is needed.
What could go wrong
This was an early-phase trial in healthy volunteers, not patients. The study was terminated, so results are limited. It is unclear if it will work in real-world bleeding emergencies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Frontage Clinical Services
Secaucus, New Jersey, 07094, United States
-
ICON Early Phase Services, LLC
San Antonio, Texas, 78209, United States
-
Qps-Mra, Llc.
South Miami, Florida, 33143, United States